Estrogen-like Compounds in Diet May Reduce Effectiveness of Breast Cancer Treatment

Estrogen-like Compounds in Diet May Reduce Effectiveness of Breast Cancer Treatment
Breast cancer patients taking Ibrance (palbociclib) plus Femara (letrozole), an approved combination for the disease, should avoid diets rich in estrogen-like compounds, researchers say. Their research shows that these compounds, called xenoestrogens, can largely hamper the effectiveness of the medicines, even if present in just small amounts. The investigators tested the effects of two compounds — genistein and zearalenone — found in soybeans, maize, barley, wheat, and other grains, but believe this is just the tip of the iceberg, and many other xenoestrogens may have similar effects. "Breast cancer patients taking palbociclib/letrozole should consider limiting their exposure to foods that contain xenoestrogens," Gary Siuzdak, PhD, senior director of the Center for Metabolomics of The Scripps Research Institute (TSRI), said in a news release. The study, “Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy,” was published in the journal Cell Chemical Biology. The combination of Ibrance and Femara received accelerated approval from the U.S. Food and Drug Administration in February 2015, and the FDA is
Subscribe or to access all post and page content.